시장조사 보고서 : 세계의 면역 체크포인트 억제제 시장예측 2021년-2026년

■ 영문 제목 : Global Immune Checkpoint Inhibitors Market Growth 2021-2026
	■ 상품코드 : LPI-2201K00059 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 12월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 91 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료, 제약

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1명 열람용)	USD3,660 ⇒환산￦4,941,000	견적의뢰/주문/질문
Multi User (5명 열람용)	USD5,490 ⇒환산￦7,411,500	견적의뢰/주문/질문
Corporate User (동일기업내 공유가능)	USD7,320 ⇒환산￦9,882,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

본 조사보고서는 면역 체크포인트 억제제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (PD-1/PD-L1, CTLA-4)와 용도별 시장규모 (폐암, 결장 직장암, 유방암, 전립선암, 흑색종, 혈액암, 기타) 데이터도 수록되어 있습니다.
- 조사 범위
- 경영자용 요약
- 기업별 면역 체크포인트 억제제 시장 점유율
- 지역별 면역 체크포인트 억제제 시장규모
- 주요지역의 종류별 시장규모 (PD-1/PD-L1, CTLA-4)
- 주요지역의 용도별 시장규모 (폐암, 결장 직장암, 유방암, 전립선암, 흑색종, 혈액암, 기타)
- 미주의 면역 체크포인트 억제제 시장규모 (미국, 캐나다, 멕시코, 브라질 등)
- 아시아의 면역 체크포인트 억제제 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등)
- 유럽의 면역 체크포인트 억제제 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등)
- 중동/아프리카의 면역 체크포인트 억제제 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등)
- 시장의 성장요인, 과제, 동향
- 마케팅, 유통업자, 고객리스트
- 세계의 면역 체크포인트 억제제 시장예측 (2021년-2026년)
- 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익)
Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences
- 조사의 결과/결론

■ 보고서 개요

According to this latest study, the 2021 growth of Immune Checkpoint Inhibitors will have significant change from previous year. By the most conservative estimates of global Immune Checkpoint Inhibitors market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 12270 million in 2020. Over the next five years the Immune Checkpoint Inhibitors market will register a 16.7% CAGR in terms of revenue, the global market size will reach US$ 22750 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
PD-1/PD-L1
CTLA-4

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences

■ 보고서 목차

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Immune Checkpoint Inhibitors Consumption 2016-2026
2.1.2 Immune Checkpoint Inhibitors Consumption CAGR by Region
2.2 Immune Checkpoint Inhibitors Segment by Type
2.2.1 PD-1/PD-L1
2.2.2 CTLA-4
2.3 Immune Checkpoint Inhibitors Sales by Type
2.3.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
2.3.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Type (2016-2021)
2.3.3 Global Immune Checkpoint Inhibitors Sale Price by Type (2016-2021)
2.4 Immune Checkpoint Inhibitors Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 Breast Cancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancer
2.4.7 Other
2.5 Immune Checkpoint Inhibitors Sales by Application
2.5.1 Global Immune Checkpoint Inhibitors Sale Market Share by Application (2016-2021)
2.5.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Application (2016-2021)
2.5.3 Global Immune Checkpoint Inhibitors Sale Price by Application (2016-2021)

3 Global Immune Checkpoint Inhibitors by Company
3.1 Global Immune Checkpoint Inhibitors Sales Market Share by Company
3.1.1 Global Immune Checkpoint Inhibitors Sales by Company (2019-2021)
3.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Company (2019-2021)
3.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Company
3.2.1 Global Immune Checkpoint Inhibitors Revenue by Company (2019-2021)
3.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Company (2019-2021)
3.3 Global Immune Checkpoint Inhibitors Sale Price by Company
3.4 Global Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Inhibitors Product Location Distribution
3.4.2 Players Immune Checkpoint Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Immune Checkpoint Inhibitors by Region
4.1 Global Immune Checkpoint Inhibitors by Region
4.1.1 Global Immune Checkpoint Inhibitors Sales by Region
4.1.2 Global Immune Checkpoint Inhibitors Revenue by Region
4.2 Americas Immune Checkpoint Inhibitors Sales Growth
4.3 APAC Immune Checkpoint Inhibitors Sales Growth
4.4 Europe Immune Checkpoint Inhibitors Sales Growth
4.5 Middle East & Africa Immune Checkpoint Inhibitors Sales Growth

5 Americas
5.1 Americas Immune Checkpoint Inhibitors Sales by Country
5.1.1 Americas Immune Checkpoint Inhibitors Sales by Country (2016-2021)
5.1.2 Americas Immune Checkpoint Inhibitors Revenue by Country (2016-2021)
5.2 Americas Immune Checkpoint Inhibitors Sales by Type
5.3 Americas Immune Checkpoint Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Immune Checkpoint Inhibitors Sales by Region
6.1.1 APAC Immune Checkpoint Inhibitors Sales by Region (2016-2021)
6.1.2 APAC Immune Checkpoint Inhibitors Revenue by Region (2016-2021)
6.2 APAC Immune Checkpoint Inhibitors Sales by Type
6.3 APAC Immune Checkpoint Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Immune Checkpoint Inhibitors by Country
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Country (2016-2021)
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Country (2016-2021)
7.2 Europe Immune Checkpoint Inhibitors Sales by Type
7.3 Europe Immune Checkpoint Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Immune Checkpoint Inhibitors by Country
8.1.1 Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2016-2021)
8.1.2 Middle East & Africa Immune Checkpoint Inhibitors Revenue by Country (2016-2021)
8.2 Middle East & Africa Immune Checkpoint Inhibitors Sales by Type
8.3 Middle East & Africa Immune Checkpoint Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Immune Checkpoint Inhibitors Distributors
10.3 Immune Checkpoint Inhibitors Customer

11 Global Immune Checkpoint Inhibitors Market Forecast
11.1 Global Immune Checkpoint Inhibitors Forecast by Region
11.1.1 Global Immune Checkpoint Inhibitors Forecast by Regions (2021-2026)
11.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Immune Checkpoint Inhibitors Forecast by Type
11.7 Global Immune Checkpoint Inhibitors Forecast by Application

12 Key Players Analysis
12.1 Bristol Myer Squibb
12.1.1 Bristol Myer Squibb Company Information
12.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Offered
12.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Bristol Myer Squibb Main Business Overview
12.1.5 Bristol Myer Squibb Latest Developments
12.2 AstraZeneca
12.2.1 AstraZeneca Company Information
12.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Offered
12.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 AstraZeneca Main Business Overview
12.2.5 AstraZeneca Latest Developments
12.3 Merck
12.3.1 Merck Company Information
12.3.2 Merck Immune Checkpoint Inhibitors Product Offered
12.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Merck Main Business Overview
12.3.5 Merck Latest Developments
12.4 Roche / Genentech
12.4.1 Roche / Genentech Company Information
12.4.2 Roche / Genentech Immune Checkpoint Inhibitors Product Offered
12.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Roche / Genentech Main Business Overview
12.4.5 Roche / Genentech Latest Developments
12.5 Ono Pharmaceutical
12.5.1 Ono Pharmaceutical Company Information
12.5.2 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Offered
12.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Ono Pharmaceutical Main Business Overview
12.5.5 Ono Pharmaceutical Latest Developments
12.6 Regeneron
12.6.1 Regeneron Company Information
12.6.2 Regeneron Immune Checkpoint Inhibitors Product Offered
12.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Regeneron Main Business Overview
12.6.5 Regeneron Latest Developments
12.7 Innovent
12.7.1 Innovent Company Information
12.7.2 Innovent Immune Checkpoint Inhibitors Product Offered
12.7.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Innovent Main Business Overview
12.7.5 Innovent Latest Developments
12.8 Hengrui Medicine
12.8.1 Hengrui Medicine Company Information
12.8.2 Hengrui Medicine Immune Checkpoint Inhibitors Product Offered
12.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Hengrui Medicine Main Business Overview
12.8.5 Hengrui Medicine Latest Developments
12.9 Junshi Biosciences
12.9.1 Junshi Biosciences Company Information
12.9.2 Junshi Biosciences Immune Checkpoint Inhibitors Product Offered
12.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Junshi Biosciences Main Business Overview
12.9.5 Junshi Biosciences Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Immune Checkpoint Inhibitors Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of PD-1/PD-L1
Table 3. Major Players of CTLA-4
Table 4. Global Immune Checkpoint Inhibitors Sales by Type (2016-2021) & (MT)
Table 5. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 6. Global Immune Checkpoint Inhibitors Revenue by Type (2016-2021) & ($ million)
Table 7. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
Table 8. Global Immune Checkpoint Inhibitors Sale Price by Type (2016-2021)
Table 9. Global Immune Checkpoint Inhibitors Sales by Application (2016-2021) & (MT)
Table 10. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 11. Global Immune Checkpoint Inhibitors Value by Application (2016-2021)
Table 12. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
Table 13. Global Immune Checkpoint Inhibitors Sale Price by Application (2016-2021)
Table 14. Global Immune Checkpoint Inhibitors Sales by Company (2019-2021) & (MT)
Table 15. Global Immune Checkpoint Inhibitors Sales Market Share by Company (2019-2021)
Table 16. Global Immune Checkpoint Inhibitors Revenue by Company (2019-2021) ($ Millions)
Table 17. Global Immune Checkpoint Inhibitors Revenue Market Share by Company (2019-2021)
Table 18. Global Immune Checkpoint Inhibitors Sale Price by Company (2019-2021)
Table 19. Key Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution and Sales Area
Table 20. Players Immune Checkpoint Inhibitors Products Offered
Table 21. Immune Checkpoint Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 22. New Products and Potential Entrants
Table 23. Mergers & Acquisitions, Expansion
Table 24. Global Immune Checkpoint Inhibitors Sales by Region (2016-2021) (MT)
Table 25. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
Table 26. Global Immune Checkpoint Inhibitors Revenue by Region (2016-2021) & ($ Millions)
Table 27. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
Table 28. Americas Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 29. Americas Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 30. Americas Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & ($ Millions)
Table 31. Americas Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 32. Americas Immune Checkpoint Inhibitors Sales by Type (2016-2021) & (MT)
Table 33. Americas Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 34. Americas Immune Checkpoint Inhibitors Sales by Application (2016-2021) & (MT)
Table 35. Americas Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 36. APAC Immune Checkpoint Inhibitors Sales by Region (2016-2021) & (MT)
Table 37. APAC Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
Table 38. APAC Immune Checkpoint Inhibitors Revenue by Region (2016-2021) & ($ Millions)
Table 39. APAC Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
Table 40. APAC Immune Checkpoint Inhibitors Sales by Type (2016-2021) & (MT)
Table 41. APAC Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 42. APAC Immune Checkpoint Inhibitors Sales by Application (2016-2021) & (MT)
Table 43. APAC Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 44. Europe Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 45. Europe Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 46. Europe Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & ($ Millions)
Table 47. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 48. Europe Immune Checkpoint Inhibitors Sales by Type (2016-2021) & (MT)
Table 49. Europe Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 50. Europe Immune Checkpoint Inhibitors Sales by Application (2016-2021) & (MT)
Table 51. Europe Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 52. Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2016-2021) & (MT)
Table 53. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2016-2021)
Table 54. Middle East & Africa Immune Checkpoint Inhibitors Revenue by Country (2016-2021) & ($ Millions)
Table 55. Middle East & Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2016-2021)
Table 56. Middle East & Africa Immune Checkpoint Inhibitors Sales by Type (2016-2021) & (MT)
Table 57. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
Table 58. Middle East & Africa Immune Checkpoint Inhibitors Sales by Application (2016-2021) & (MT)
Table 59. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Table 60. Key and Potential Regions of Immune Checkpoint Inhibitors
Table 61. Key Application and Potential Industries of Immune Checkpoint Inhibitors
Table 62. Key Challenges of Immune Checkpoint Inhibitors
Table 63. Key Trends of Immune Checkpoint Inhibitors
Table 64. Immune Checkpoint Inhibitors Distributors List
Table 65. Immune Checkpoint Inhibitors Customer List
Table 66. Global Immune Checkpoint Inhibitors Sales Forecast by Region (2021-2026) & (MT)
Table 67. Global Immune Checkpoint Inhibitors Consumption Market Forecast by Region
Table 68. Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2021-2026) & ($ millions)
Table 69. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Region (2021-2026)
Table 70. Americas Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) & (MT)
Table 71. Americas Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) & ($ millions)
Table 72. APAC Immune Checkpoint Inhibitors Sales Forecast by Region (2021-2026) & (MT)
Table 73. APAC Immune Checkpoint Inhibitors Revenue Forecast by Region (2021-2026) & ($ millions)
Table 74. Europe Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) & (MT)
Table 75. Europe Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) & ($ millions)
Table 76. Middle East & Africa Immune Checkpoint Inhibitors Sales Forecast by Country (2021-2026) & (MT)
Table 77. Middle East & Africa Immune Checkpoint Inhibitors Revenue Forecast by Country (2021-2026) & ($ millions)
Table 78. Global Immune Checkpoint Inhibitors Sales Forecast by Type (2021-2026) & (MT)
Table 79. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Type (2021-2026)
Table 80. Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 81. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Type (2021-2026)
Table 82. Global Immune Checkpoint Inhibitors Sales Forecast by Application (2021-2026) & (MT)
Table 83. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Application (2021-2026)
Table 84. Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 85. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Application (2021-2026)
Table 86. Bristol Myer Squibb Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 87. Bristol Myer Squibb Immune Checkpoint Inhibitors Product Offered
Table 88. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 89. Bristol Myer Squibb Main Business
Table 90. Bristol Myer Squibb Latest Developments
Table 91. AstraZeneca Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 92. AstraZeneca Immune Checkpoint Inhibitors Product Offered
Table 93. AstraZeneca Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 94. AstraZeneca Main Business
Table 95. AstraZeneca Latest Developments
Table 96. Merck Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 97. Merck Immune Checkpoint Inhibitors Product Offered
Table 98. Merck Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 99. Merck Main Business
Table 100. Merck Latest Developments
Table 101. Roche / Genentech Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 102. Roche / Genentech Immune Checkpoint Inhibitors Product Offered
Table 103. Roche / Genentech Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 104. Roche / Genentech Main Business
Table 105. Roche / Genentech Latest Developments
Table 106. Ono Pharmaceutical Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 107. Ono Pharmaceutical Immune Checkpoint Inhibitors Product Offered
Table 108. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 109. Ono Pharmaceutical Main Business
Table 110. Ono Pharmaceutical Latest Developments
Table 111. Regeneron Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 112. Regeneron Immune Checkpoint Inhibitors Product Offered
Table 113. Regeneron Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 114. Regeneron Main Business
Table 115. Regeneron Latest Developments
Table 116. Innovent Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 117. Innovent Immune Checkpoint Inhibitors Product Offered
Table 118. Innovent Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 119. Innovent Main Business
Table 120. Innovent Latest Developments
Table 121. Hengrui Medicine Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 122. Hengrui Medicine Immune Checkpoint Inhibitors Product Offered
Table 123. Hengrui Medicine Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 124. Hengrui Medicine Main Business
Table 125. Hengrui Medicine Latest Developments
Table 126. Junshi Biosciences Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 127. Junshi Biosciences Immune Checkpoint Inhibitors Product Offered
Table 128. Junshi Biosciences Immune Checkpoint Inhibitors Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2019-2021E)
Table 129. Junshi Biosciences Main Business
Table 130. Junshi Biosciences Latest Developments
List of Figures
Figure 1. Picture of Immune Checkpoint Inhibitors
Figure 2. Immune Checkpoint Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Checkpoint Inhibitors Sales Growth Rate 2016-2026 (MT)
Figure 7. Global Immune Checkpoint Inhibitors Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Immune Checkpoint Inhibitors Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of PD-1/PD-L1
Figure 10. Product Picture of CTLA-4
Figure 11. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2020
Figure 12. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
Figure 13. Immune Checkpoint Inhibitors Consumed in Lung Cancer
Figure 14. Global Immune Checkpoint Inhibitors Market: Lung Cancer (2016-2021) & (MT)
Figure 15. Immune Checkpoint Inhibitors Consumed in Colorectal Cancer
Figure 16. Global Immune Checkpoint Inhibitors Market: Colorectal Cancer (2016-2021) & (MT)
Figure 17. Immune Checkpoint Inhibitors Consumed in Breast Cancer
Figure 18. Global Immune Checkpoint Inhibitors Market: Breast Cancer (2016-2021) & (MT)
Figure 19. Immune Checkpoint Inhibitors Consumed in Prostate Cancer
Figure 20. Global Immune Checkpoint Inhibitors Market: Prostate Cancer (2016-2021) & (MT)
Figure 21. Immune Checkpoint Inhibitors Consumed in Melanoma
Figure 22. Global Immune Checkpoint Inhibitors Market: Melanoma (2016-2021) & (MT)
Figure 23. Immune Checkpoint Inhibitors Consumed in Blood Cancer
Figure 24. Global Immune Checkpoint Inhibitors Market: Blood Cancer (2016-2021) & (MT)
Figure 25. Immune Checkpoint Inhibitors Consumed in Other
Figure 26. Global Immune Checkpoint Inhibitors Market: Other (2016-2021) & (MT)
Figure 27. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
Figure 28. Global Immune Checkpoint Inhibitors Revenue Market Share by Application in 2020
Figure 29. Immune Checkpoint Inhibitors Revenue Market by Company in 2020 ($ Million)
Figure 30. Global Immune Checkpoint Inhibitors Revenue Market Share by Company in 2020
Figure 31. Global Immune Checkpoint Inhibitors Sales Market Share by Regions (2016-2021)
Figure 32. Global Immune Checkpoint Inhibitors Revenue Market Share by Region in 2020
Figure 33. Americas Immune Checkpoint Inhibitors Sales 2016-2021 (MT)
Figure 34. Americas Immune Checkpoint Inhibitors Revenue 2016-2021 ($ Millions)
Figure 35. APAC Immune Checkpoint Inhibitors Sales 2016-2021 (MT)
Figure 36. APAC Immune Checkpoint Inhibitors Revenue 2016-2021 ($ Millions)
Figure 37. Europe Immune Checkpoint Inhibitors Sales 2016-2021 (MT)
Figure 38. Europe Immune Checkpoint Inhibitors Revenue 2016-2021 ($ Millions)
Figure 39. Middle East & Africa Immune Checkpoint Inhibitors Sales 2016-2021 (MT)
Figure 40. Middle East & Africa Immune Checkpoint Inhibitors Revenue 2016-2021 ($ Millions)
Figure 41. Americas Immune Checkpoint Inhibitors Sales Market Share by Country in 2020
Figure 42. Americas Immune Checkpoint Inhibitors Revenue Market Share by Country in 2020
Figure 43. Americas Immune Checkpoint Inhibitors Sales Market Share by Type in 2020
Figure 44. Americas Immune Checkpoint Inhibitors Sales Market Share by Application in 2020
Figure 45. United States Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 46. Canada Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 47. Mexico Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 48. Brazil Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 49. APAC Immune Checkpoint Inhibitors Sales Market Share by Region in 2020
Figure 50. APAC Immune Checkpoint Inhibitors Revenue Market Share by Regions in 2020
Figure 51. APAC Immune Checkpoint Inhibitors Sales Market Share by Type in 2020
Figure 52. APAC Immune Checkpoint Inhibitors Sales Market Share by Application in 2020
Figure 53. China Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 54. Japan Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 55. Korea Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 56. Southeast Asia Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 57. India Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 58. Australia Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 59. Europe Immune Checkpoint Inhibitors Sales Market Share by Country in 2020
Figure 60. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country in 2020
Figure 61. Europe Immune Checkpoint Inhibitors Sales Market Share by Type in 2020
Figure 62. Europe Immune Checkpoint Inhibitors Sales Market Share by Application in 2020
Figure 63. Germany Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 64. France Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 65. UK Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 66. Italy Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 67. Russia Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 68. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Country in 2020
Figure 69. Middle East & Africa Immune Checkpoint Inhibitors Revenue Market Share by Country in 2020
Figure 70. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Type in 2020
Figure 71. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Application in 2020
Figure 72. Egypt Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 73. South Africa Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 74. Israel Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 75. Turkey Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 76. GCC Country Immune Checkpoint Inhibitors Revenue Growth 2016-2021 ($ Millions)
Figure 77. Channels of Distribution
Figure 78. Distributors Profiles

※본 조사보고서 [세계의 면역 체크포인트 억제제 시장예측 2021년-2026년] (코드 : LPI-2201K00059) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 면역 체크포인트 억제제 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 조사자료도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 면역 레퍼토리 시퀀스 시장예측 2021년-2026년
LPI-2201K00151 / LP Information / 2021년 12월 / 본 조사보고서는 면역 레퍼토리 시퀀스의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Immune Repertoire Sequencing will have significant change from previous year. By the most conservative estimates of global Immune Repertoire Sequencing market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 101 million in...

세계의 면역 건강 보조 식품 시장예측 2021년-2026년
LPI-2201K00060 / LP Information / 2021년 12월 / 본 조사보고서는 면역 건강 보조 식품의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스,...According to this latest study, the 2021 growth of Immune Health Supplements will have significant change from previous year. By the most conservative estimates of global Immune Health Supplements market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 39510 million in...

세계의 면역종양학 시장예측 2021년-2026년
LPI-2201K00152 / LP Information / 2021년 12월 / 본 조사보고서는 면역종양학의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아,...According to this latest study, the 2021 growth of Immuno-Oncology will have significant change from previous year. By the most conservative estimates of global Immuno-Oncology market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 37120 million in 2020. Over the next...

세계의 유성 부식 억제제 시장예측 2021년-2026년
LPI-2201K03031 / LP Information / 2021년 12월 / 본 조사보고서는 유성 부식 억제제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Oil-base Corrosion Inhibitors will have significant change from previous year. By the most conservative estimates of global Oil-base Corrosion Inhibitors market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in...

세계의 말초 신경 복구 시장예측 2021년-2026년
LPI-2201K02472 / LP Information / 2021년 12월 / 본 조사보고서는 말초 신경 복구의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Peripheral Nerve Repair will have significant change from previous year. By the most conservative estimates of global Peripheral Nerve Repair market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 172.6 million in...